Scarica l'app Stockscreener
4.08
4.62%
0.18
Dopo l'orario di chiusura:
4.07
-0.010
-0.25%
Precedente Chiudi:
$3.90
Aprire:
$3.88
Volume 24 ore:
18,834
Relative Volume:
0.55
Capitalizzazione di mercato:
$116.77M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+10.87%
1M Prestazione:
+32.47%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$3.76
$4.12
Intervallo di 1 settimana:
$3.5474
$4.12
Portata 52W:
$2.33
$4.12
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Nome
Insight Molecular Diagnostics Inc
Settore
Industria
Telefono
949-409-7600
Indirizzo
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Confronta IMDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
4.08 | 111.62M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
525.83 | 198.09B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
206.15 | 146.89B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
636.91 | 50.67B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
138.04 | 39.19B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
204.76 | 34.64B | 15.70B | 1.24B | 2.01B | 6.9036 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-28 | Iniziato | Lake Street | Buy |
| 2022-05-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-03-17 | Ripresa | Needham | Buy |
| 2021-01-07 | Aggiornamento | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Iniziato | BTIG Research | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Reiterato | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Iniziato | Needham | Buy |
| 2019-02-13 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-29 | Aggiornamento | Janney | Neutral → Buy |
| 2018-12-19 | Ripresa | Lake Street | Buy |
Mostra tutto
Insight Molecular Diagnostics Inc Borsa (IMDX) Ultime notizie
Insight Molecular Diagnostics names Steven Tahmooressi as VP, marketing - Medical Buyer
Insight Molecular Diagnostics appoints Steven Tahmooressi as VP of Marketing - Investing.com Nigeria
Imdx welcomes new VP Marketing to prepare for commercial transplant assay launch - MarketScreener
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch - GlobeNewswire
GraftAssureDx kit launching 2026: iMDx hires Steven Tahmooressi as VP Marketing to lead global rollout - Stock Titan
What earnings margins imply for Insight Molecular Diagnostics Inc. (7OC0) stockQuarterly Trade Review & Long-Term Growth Portfolio Plans - newser.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock included in top ETFsJuly 2025 Patterns & Community Consensus Trade Alerts - newser.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock dividend growth reliable - newser.com
Will Insight Molecular Diagnostics Inc. (7OC0) stock attract long term capital inflowsQuarterly Profit Report & Accurate Technical Buy Alerts - newser.com
Bullish Insight Molecular Diagnostics Insiders Rewarded As Their Investment Rises To US$4.85m - simplywall.st
Insight Molecular Diagnostics Inc.'s (NASDAQ:IMDX) large hedge funds owners must be happy as stock continues to impress, up 12% over the past week - Yahoo Finance
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring - Sahm
Insight Molecular Diagnostics stock rises after transplant study publication - Investing.com
Insight Molecular Says GraftAssure Assay Helped Avoid Overtreatment in Kidney Transplant Patient - MarketScreener
IMDX's GraftAssure Assay Shows Promise in Kidney Transplant Moni - GuruFocus
GraftAssure test helps monitor kidney transplant patient during cancer therapy By Investing.com - Investing.com Nigeria
Imdx reports kidney transplant patient achieved 'immune reset' with novel therapy and GraftAssure monitoring - MarketScreener
Molecular Diagnostics Market Analysis: Trends, Opportunities, and Forecast - newstrail.com
Why Insight Molecular Diagnostics Inc. (7OC0) stock benefits from AI revolutionJuly 2025 Price Swings & Community Trade Idea Sharing Platform - newser.com
Insight Molecular Diagnostics Extends Executive Employment Agreement - TipRanks
Insight Molecular Diagnostics grants stock options to executives and amends employment agreement - Investing.com
What analysts say about Insight Molecular Diagnostics Inc 7OC0 stockContrarian Investment Ideas & Stay Invested. Stay Smart. - earlytimes.in
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛
Autoimmune Disease Diagnostics Market Size Report, 2034 - Global Market Insights Inc.
Why Insight Molecular Diagnostics Inc. (7OC0) stock fits value portfoliosQuarterly Market Review & Smart Allocation Stock Tips - newser.com
Analysts Are Bullish on Top Healthcare Stocks: Evaxion Biotech (EVAX), Azitra Inc (AZTR) - The Globe and Mail
Molecular Diagnostics in Pharmacogenomics Market to Reach USD - openPR.com
HOLX to Discontinue Fluoroscan InSight FD Soon: Will the Stock Suffer? - TradingView
Insight Molecular Diagnostics (IMDX) Highlights GraftAssur at In - GuruFocus
Analysts’ Top Healthcare Picks: CareDx (CDNA), Semler Scientific (SMLR) - The Globe and Mail
Insight Molecular Diagnostics to Showcase Leadership in - GlobeNewswire
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando - MarketScreener
Insight Molecular Diagnostics Approves Executive Salary Increases - TipRanks
Co-Diagnostics, Inc. Signs Strategic MOU with Partner in Kingdom of Saudi Arabia to Introduce Co-Dx™ PCR Platform to Middle East - Quantisnow
North America In Vitro Diagnostics (IVD) Market Insights and Future Outlook - openPR.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX) - The Globe and Mail
iMDx launches 5,000-patient registry to study transplant rejection test - Investing.com
iMDx launches 5,000-patient registry to study transplant rejection test By Investing.com - Investing.com Nigeria
Insight Molecular Diagnostics (IMDX) Launches New Patient Regist - GuruFocus
IMDX Advances GraftAssureDx Clinical Trial for Transplant Rejection Test - GuruFocus
Insight Molecular Diagnostics Inc Azioni (IMDX) Dati Finanziari
Non sono disponibili dati finanziari per Insight Molecular Diagnostics Inc (IMDX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.95%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):